Figure 6
Figure 6. IL-15 treatment does not lead to long-lasting (day 48) accumulation of NK and memory T cells, but chronically alters the balance of CD4+ and CD8+ T cells. (A) Frequency of total T (CD3+) cells and NK (either CD56+ or CD16+) cells relative to the frequency of B (CD20+) cells in the lymphocyte gate and (B) percentage of CD56+CD16− NK cells, CD56−CD16+ NK cells, and CD95+ memory CD4+ and CD8+ T cells as found in different tissues at day 48 after treatment with IL-15. (C) Top, representative example of the percentage of the CD4+ and CD8+ cells inside the CD3+ gate in the MLN, ALN, and ILN at the same time point. Bottom, CD4:CD8 ratio as found in different tissues and in the PBMCs at day 48 after treatment with IL-15. Data in panels A through C were expressed as in Figure 3B. *P < .05 after Wilcoxon rank test versus sham.

IL-15 treatment does not lead to long-lasting (day 48) accumulation of NK and memory T cells, but chronically alters the balance of CD4+and CD8+T cells. (A) Frequency of total T (CD3+) cells and NK (either CD56+ or CD16+) cells relative to the frequency of B (CD20+) cells in the lymphocyte gate and (B) percentage of CD56+CD16− NK cells, CD56−CD16+ NK cells, and CD95+ memory CD4+ and CD8+ T cells as found in different tissues at day 48 after treatment with IL-15. (C) Top, representative example of the percentage of the CD4+ and CD8+ cells inside the CD3+ gate in the MLN, ALN, and ILN at the same time point. Bottom, CD4:CD8 ratio as found in different tissues and in the PBMCs at day 48 after treatment with IL-15. Data in panels A through C were expressed as in Figure 3B. *P < .05 after Wilcoxon rank test versus sham.

Close Modal

or Create an Account

Close Modal
Close Modal